In its petition on the AKI crisis, GALA urged the president to act swiftly on the 29 recommendations put forward by the ...

Renal replacement therapy (RRT) was initiated in cases of hepatorenal syndrome-acute kidney injury refractory to pharmacological therapy, particularly when accompanied by volume overload, severe ...

Three critically ill patients treated with procizumab experience a full reversal of cardiogenic shock in 48 hours.

The US Food and Drug Administration (FDA) has instructed all GLP-1 drug-makers to update their warning labels to include the ...

Excedrin Migraine is easily accessible and does work for many, but it may not be wise to rely on it for treating frequent migraine attacks.

Arch Biopartners has initiated subject recruitment in its Phase II study aimed at assessing cilastatin’s efficacy in ...

While hydroxychloroquine (HCQ) helps reduce disease flares in lupus, its effect on renal function in patients with lupus ...

Akebia Therapeutics, Inc. (NASDAQ:AKBA) is one of the best high-return penny stocks to buy now. On July 14, 2025, Akebia ...

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury and organ damage caused by inflammation. The Company is developing a platform of novel drugs ...

Researchers discovered that mitochondria-rich extracellular vesicles (Ti-mitoEVs) from skeletal muscle can deliver healthy ...

Hypertension affects 6% of all children and adolescents and is increasing in prevalence. Research clarifies the long-term kidney consequences.